Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases
Sherine E. Gabriel,Kaleb Michaud +1 more
Reads0
Chats0
TLDR
Strong evidence now shows that people with RA are at a high risk for developing several comorbid disorders, that these conditions may have atypical features and thus may be difficult to diagnose, and that persons with RA experience poorer outcomes after comorbridity compared with the general population.Abstract:
Epidemiology is the study of the distribution and determinants of disease in human populations. Over the past decade there has been considerable progress in our understanding of the fundamental descriptive epidemiology (levels of disease frequency: incidence and prevalence, comorbidity, mortality, trends over time, geographic distributions, and clinical characteristics) of the rheumatic diseases. This progress is reviewed for the following major rheumatic diseases: rheumatoid arthritis (RA), juvenile rheumatoid arthritis, psoriatic arthritis, osteoarthritis, systemic lupus erythematosus, giant cell arteritis, polymyalgia rheumatica, gout, Sjogren's syndrome, and ankylosing spondylitis. These findings demonstrate the dynamic nature of the incidence and prevalence of these conditions – a reflection of the impact of genetic and environmental factors. The past decade has also brought new insights regarding the comorbidity associated with rheumatic diseases. Strong evidence now shows that persons with RA are at a high risk for developing several comorbid disorders, that these conditions may have atypical features and thus may be difficult to diagnose, and that persons with RA experience poorer outcomes after comorbidity compared with the general population. Taken together, these findings underscore the complexity of the rheumatic diseases and highlight the key role of epidemiological research in understanding these intriguing conditions.read more
Citations
More filters
Journal ArticleDOI
Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis
Beatrix Bartok,Gary S. Firestein +1 more
TL;DR: Rheumatoid FLS develop a unique aggressive phenotype that increases invasiveness into the extracellular matrix and further exacerbates joint damage, and new agents that target FLS could potentially complement the current therapies without major deleterious effect on adaptive immune responses.
Journal ArticleDOI
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)
Maxime Dougados,Martin Soubrier,Anna Antunez,Peter V. Balint,Alejandro Balsa,Maya H Buch,Maya H Buch,Gustavo Casado,Jacqueline Detert,Bassel Elzorkany,Paul Emery,Paul Emery,Najia Hajjaj-Hassouni,Masayoshi Harigai,Shue Fen Luo,Reka Kurucz,Gabriel Maciel,Emilio Martin Mola,Carlomaurizio Montecucco,Iain B. McInnes,Helga Radner,Josef S Smolen,Yeong Wook Song,Harald E. Vonkeman,Kevin L. Winthrop,Jonathan Kay +25 more
TL;DR: In this multinational sample of rheumatoid arthritis patients, variability among countries was wide, not only in prevalence but also in compliance with recommendations for preventing and managing these comorbidities.
Journal ArticleDOI
All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study.
TL;DR: Patients with osteoarthritis are at higher risk of death compared with the general population, and history of diabetes, cancer, or cardiovascular disease and the presence of walking disability are major risk factors.
Journal ArticleDOI
The Lifetime Risk of Adult-Onset Rheumatoid Arthritis and Other Inflammatory Autoimmune Rheumatic Diseases
Cynthia S. Crowson,Eric L. Matteson,Elena Myasoedova,Clement J. Michet,Floranne C. Ernste,Kenneth J. Warrington,John M. Davis,Gene G. Hunder,Terry M. Therneau,Sherine E. Gabriel +9 more
TL;DR: One in 12 women and 1 in 20 men will develop an inflammatory autoimmune rheumatic disease during their lifetime, which can serve as useful guides in counseling patients regarding their lifetime risk of these conditions and have important implications regarding disease awareness campaigns.
References
More filters
Journal ArticleDOI
Prediction of Coronary Heart Disease Using Risk Factor Categories
Peter W.F. Wilson,Ralph B. D'Agostino,Daniel Levy,Albert M. Belanger,Halit Silbershatz,William B. Kannel +5 more
TL;DR: A simple coronary disease prediction algorithm was developed using categorical variables, which allows physicians to predict multivariate CHD risk in patients without overt CHD.
Journal ArticleDOI
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II.
Reva C. Lawrence,David T. Felson,Charles G. Helmick,Lesley M. Arnold,Hyon K. Choi,Richard A. Deyo,Sherine E. Gabriel,Rosemarie Hirsch,Marc C. Hochberg,Gene G. Hunder,Joanne M. Jordan,Jeffrey N. Katz,Hilal Maradit Kremers,Frederick Wolfe +13 more
TL;DR: This report provides the best available prevalence estimates for the US for osteoarthritis, polymyalgia rheumatica, gout, fibromyalgia, and carpal tunnel syndrome as well as the symptoms of neck and back pain.
National Arthritis Data Work-group. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II
Reva C. Lawrence,David T. Felson,Charles G. Helmick,LM Arnold,Hyon K. Choi,Richard A. Deyo,LM Helmick Cg Arnold,Sherine E. Gabriel,Rosemarie Hirsch,Marc C. Hochberg,Gene G. Hunder,Joanne M. Jordan,Jeffrey N. Katz,Hilal Maradit Kremers,Frederick Wolfe,FC Arnett +15 more
TL;DR: In this paper, the best available estimates of the US prevalence of and number of individuals affected by osteoarthritis, polymyalgia rheumatica and giant cell arteritis, gout, fibromyalgia, and carpal tunnel syndrome, as well as the symptoms of neck and back pain are provided.
Journal ArticleDOI
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
Joseph Keane,Sharon K. Gershon,Robert P. Wise,Elizabeth Mirabile-Levens,John Kasznica,William D. Schwieterman,Jeffrey Siegel,M. Miles Braun +7 more
TL;DR: Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis but there is no direct evidence of a protective role of TNF- α in patients with tuberculosis.
Journal ArticleDOI
Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States
Reva C. Lawrence,Charles G. Helmick,Frank C. Arnett,Richard A. Deyo,David T. Felson,Edward H. Giannini,Stephen P. Heyse,Rosemarie Hirsch,Marc C. Hochberg,Gene G. Hunder,Matthew H. Liang,Stanley R. Pillemer,Virginia D. Steen,Frederick Wolfe +13 more
TL;DR: Given the limitations of the data on which they are based, this report provides the best available prevalence estimates for arthritis and other rheumatic conditions overall, and for selected musculoskeletal disorders, in the US population.
Related Papers (5)
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
Frank C. Arnett,Steven M. Edworthy,Daniel A. Bloch,Dennis J. McShane,James F. Fries,Norman S. Cooper,L. A. Healey,Stephen R. Kaplan,Matthew H. Liang,Harvinder S. Luthra,Thomas A. Medsger,Donald M. Mitchell,David H. Neustadt,Robert S. Pinals,Jane G. Schaller,John T. Sharp,Ronald L. Wilder,Gene G. Hunder +17 more
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Daniel Aletaha,Tuhina Neogi,Alan J. Silman,Julia Funovits,David T. Felson,Clifton O. Bingham,Neal S. Birnbaum,Gerd Burmester,Vivian P. Bykerk,Marc D. Cohen,Bernard Combe,Karen H. Costenbader,Maxime Dougados,Paul Emery,Gianfranco Ferraccioli,Johanna M. W. Hazes,Kathryn Hobbs,Tom W J Huizinga,Arthur Kavanaugh,Jonathan Kay,Tore K Kvien,Timothy J. Laing,Philip J. Mease,Henri A Ménard,Larry W. Moreland,Raymond L. Naden,Theodore Pincus,Josef S Smolen,Ewa Stanislawska-Biernat,Deborah P M Symmons,Paul P. Tak,Katherine S. Upchurch,Jiří Vencovský,Frederick Wolfe,Gillian A. Hawker +34 more
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S Smolen,Robert Landewé,Ferdinand C. Breedveld,Maya H Buch,Maya H Buch,Gerd R Burmester,Maxime Dougados,Paul Emery,Paul Emery,Cécile Gaujoux-Viala,Laure Gossec,Jackie L Nam,Jackie L Nam,Sofia Ramiro,Kevin L. Winthrop,Maarten de Wit,Daniel Aletaha,Neil Betteridge,Johannes W. J. Bijlsma,Maarten Boers,Frank Buttgereit,Bernard Combe,Maurizio Cutolo,Nemanja Damjanov,Johanna M. W. Hazes,Marios Kouloumas,Tore K Kvien,Xavier Mariette,Karel Pavelka,Piet L. C. M. van Riel,Andrea Rubbert-Roth,Marieke Scholte-Voshaar,David Scott,T. Sokka-Isler,John B. Wong,Désirée van der Heijde +35 more